Model-Based Approach To Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine

por Zhu, Min, Kaul, Sanjeev, Nandy, Partha, Grasela, Dennis M., Pfister, Marc
Publicado 2009

Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

por Ambrose, Paul G., Grasela, Dennis M., Grasela, Thaddeus H., Passarell, Julie, Mayer, Howard B., Pierce, Phillip F.
Publicado 2001

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled...

por Catlett, Ian M., Nowak, Miroslawa, Kundu, Sudeep, Zheng, Naiyu, Liu, Ang, He, Bing, Girgis, Ihab G., Grasela, Dennis M.
Publicado en Br J Clin Pharmacol (2020)

Pharmacokinetics of Single-Dose Oral Stavudine in Subjects with Renal Impairment and in Subjects Requiring Hemodialysis

por Grasela, Dennis M., Stoltz, Randall R., Barry, Michael, Bone, Michael, Mangold, Bernhard, O'Grady, Padraig, Raymond, Ralph, Haworth, Stephen J.
Publicado 2000

Pharmacokinetics of Gatifloxacin in Infants and Children

por Capparelli, Edmund V., Reed, Michael D., Bradley, John S., Kearns, Gregory L., Jacobs, Richard F., Damle, Bharat D., Blumer, Jeffrey L., Grasela, Dennis M.
Publicado 2005

Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients

por Rubino, Christopher M., Capparelli, Edmund V., Bradley, John S., Blumer, Jeffrey L., Kearns, Gregory L., Reed, Michael, Jacobs, Richard F., Cirincione, Brenda, Grasela, Dennis M.
Publicado 2007

Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects

por Hanna, George J., Lalezari, Jacob, Hellinger, James A., Wohl, David A., Nettles, Richard, Persson, Anna, Krystal, Mark, Lin, Pinfang, Colonno, Richard, Grasela, Dennis M.
Publicado 2011

Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection

por Sims, Karen D., Lemm, Julie, Eley, Timothy, Liu, Menping, Berglind, Anna, Sherman, Diane, Lawitz, Eric, Vutikullird, Apinya B., Tebas, Pablo, Gao, Min, Pasquinelli, Claudio, Grasela, Dennis M.
Publicado 2014

Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections

por Van Wart, Scott, Phillips, Luann, Ludwig, Elizabeth A., Russo, Rene, Gajjar, Diptee A., Bello, Akintunde, Ambrose, Paul G., Costanzo, Christopher, Grasela, Thaddeus H., Echols, Roger, Grasela, Dennis M.
Publicado 2004

Immune checkpoint inhibition in sepsis: a Phase 1b randomized, placebo-controlled, single ascending dose study of anti-PD-L1 (BMS-936559)

por Hotchkiss, Richard S., Colston, Elizabeth, Yende, Sachin, Angus, Derek C., Moldawer, Lyle L., Crouser, Elliott D., Martin, Greg S., Coopersmith, Craig M., Brakenridge, Scott, Mayr, Florian B., Park, Pauline K., Ye, June, Catlett, Ian M., Girgis, Ihab G., Grasela, Dennis M.
Publicado en Crit Care Med (2019)

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

por Gay, Cynthia L., Bosch, Ronald J, Ritz, Justin, Hataye, Jason M., Aga, Evgenia, Tressler, Randall L., Mason, Stephen W., Hwang, Carey K., Grasela, Dennis M., Ray, Neelanjana, Cyktor, Josh C., Coffin, John M., Acosta, Edward P., Koup, Richard A., Mellors, John W., Eron, Joseph J.
Publicado en J Infect Dis (2017)

Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C

por Pasquinelli, Claudio, McPhee, Fiona, Eley, Timothy, Villegas, Criselda, Sandy, Katrina, Sheridan, Pamela, Persson, Anna, Huang, Shu-Pang, Hernandez, Dennis, Sheaffer, Amy K., Scola, Paul, Marbury, Thomas, Lawitz, Eric, Goldwater, Ronald, Rodriguez-Torres, Maribel, DeMicco, Michael, Wright, David, Charlton, Michael, Kraft, Walter K., Lopez-Talavera, Juan-Carlos, Grasela, Dennis M.
Publicado 2012

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

por Gao, Min, Nettles, Richard E., Belema, Makonen, Snyder, Lawrence B., Nguyen, Van N., Fridell, Robert A., Serrano-Wu, Michael H., Langley, David R., Sun, Jin-Hua, O’Boyle II, Donald R., Lemm, Julie A., Wang, Chunfu, Knipe, Jay O., Chien, Caly, Colonno, Richard J., Grasela, Dennis M., Meanwell, Nicholas A., Hamann, Lawrence G.
Publicado en Nature (2010)